High Density Lipoprotein Turnover

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
The objective of the study is to evaluate the effect of Rimonabant 20mg in comparison to placebo, on HDL and VLDL lipoprotein kinetics, over a 12 months period. Primary objectives: * To assess effect of Rimonabant on HDL ApoA-I fractional catabolic rate (FCR). Secondary objectives: * To assess effect of Rimonabant on HDL ApoA-I production rate (PR) and on other lipoprotein kinetics. * To assess effect of Rimonabant on lipids, glycemic and inflammatory parameters * To assess effect of Rimonabant on body composition * To assess safety of Rimonabant
Epistemonikos ID: f6a640f4d19427b61e154f71bedd33b75165a708
First added on: May 04, 2024